Management of HCC
Management of HCC
复制标题
DOI：
10.1016/s0168-8278(12)60009-9
复制
发表时间：
2012-01-01
影响因子：
25.7
通讯作者：
Bruix, Jordi
中科院分区：
文献类型：
--
作者：
Rodriguez de Lope, Carlos;Tremosini, Silvia;Bruix, Jordi
肝细胞癌（HCC）是一种高度流行和致命的肿瘤，其治疗在过去几年中有了显着改善。更好地了解肿瘤的自然历史和分期系统的发展，根据肿瘤的特征、肝脏疾病和表现状态对患者进行分层，如BCLC（巴塞罗那临床肝癌）系统，已经导致更好的预后预测和最合适的治疗方法。今天，治愈性治疗（切除、移植、消融）可以提高早期HCC诊断患者的生存率，并提供潜在的长期治愈。中期HCC患者受益于化疗栓塞治疗，晚期HCC患者受益于索拉非尼治疗，索拉非尼是一种多激酶抑制剂，具有抗血管生成和抗增殖作用。本文就肝细胞癌的治疗现状及最新进展作一综述。
Hepatocellular carcinoma (HCC) is a highly prevalent and lethal neoplasia, the management of which has significantly improved during the last few years. A better knowledge of the natural history of the tumor and the development of staging systems that stratify patients according to the characteristics of the tumor, the liver disease, and the performance status, such as the BCLC (Barcelona Clinic Liver Cancer) system, have led to a better prediction of prognosis and to a most appropriate treatment approach. Today curative therapies (resection, transplantation, ablation) can improve survival in patients diagnosed at an early HCC stage and offer a potential long-term cure. Patients with intermediate stage HCC benefit from chemoembolization and those diagnosed at advanced stage benefit from sorafenib, a multikinase inhibitor with antiangiogenic and antiproliferative effects. In this article we review the current management in HCC and the new advances in this field.